RT Journal Article
SR Electronic
T1 Cancer predisposition syndromes as risk factor for early second primary neoplasms after childhood cancer – a national cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.05.20180612
DO 10.1101/2020.09.05.20180612
A1 Waespe, Nicolas
A1 Belle, Fabiën N.
A1 Redmond, Shelagh
A1 Schindera, Christina
A1 Spycher, Ben D.
A1 Rössler, Jochen
A1 Ansari, Marc
A1 Kuehni, Claudia E.
A1 for the Swiss Pediatric Oncology Group (SPOG)
YR 2020
UL http://medrxiv.org/content/early/2020/09/07/2020.09.05.20180612.abstract
AB Background Childhood cancer patients are at increased risk of second primary neoplasms (SPNs). We assessed incidence and risk factors for early SPNs with a focus on cancer predisposition syndromes (CPSs).Patients and methods This cohort study used data from the Swiss Childhood Cancer Registry. We included patients with first primary neoplasms (FPN) until age 21 years from 1986 to 2015 and identified SPNs occurring before age 21. We calculated standardized incidence ratios (SIR) and absolute excess risks (AER) using Swiss population cancer incidence data and cumulative incidence of SPNs. We calculated hazard ratios (HR) of risk factors for SPNs using Fine and Gray competing risk regression.Results Among 8,074 childhood cancer patients, 304 (4%) were diagnosed with a CPS and 94 (1%) developed early SPNs. The incidence of SPNs was more than 10-fold increased in childhood cancer patients compared to neoplasms in the general population (SIR 10.6, 95%-confidence interval [CI] 8.7-13.1) and the AER was 179/100,000 person-years (CI 139-219). Cumulative incidence of SPNs 20 years after FPN diagnosis was 23% in patients with CPSs and 3% in those without. Risk factors for SPNs were CPSs (HR 7.8, CI 4.8-12.7), chemotherapy (HR 2.2, CI 1.1-4.6), radiotherapy (HR 1.9, CI 1.2-2.9), hematopoietic stem cell transplantation (HR 1.8, CI 1-3.3), and older age (15-20 years) at FPN diagnosis (HR 1.9, CI 1.1-3.2).Conclusion CPSs are associated with a high risk of SPNs before age 21 years. Identification of CPSs is important for appropriate cancer surveillance and targeted screening.Competing Interest StatementThe authors have declared no competing interest.Funding StatementRole of funding source The funding sources had no role in the design of this study, its execution, analyses, interpretation of the data, or decision to submit results. The funding sources of the Swiss Childhood Cancer Registry support the daily running of the registry and have not had any role in the design, conduct, interpretation, or publication of the Swiss Childhood Cancer Registry itself as well as the related research projects. This study was supported by the CANSEARCH Foundation, the Swiss National Science Foundation (31BL30_185396), Swiss Cancer Research and the Swiss Cancer League (KLS-3886-02-2016 and KLS/KFS-4825-01-2019, KFS-4722-02-2019), "Stiftung fuer krebskranke Kinder Regio Basiliensis." The work of the Swiss Childhood Cancer Registry is supported by the Swiss Pediatric Oncology Group (www.spog.ch), Schweizerische Konferenz der kantonalen Gesundheitsdirektorinnen und -direktoren (www.gdk-cds.ch), Swiss Cancer Research (www.krebsforschung.ch), and Kinderkrebshilfe Schweiz (www.kinderkrebshilfe.ch).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee of the Canton of Bern gave its approval to the Swiss Childhood Cancer Registry, from where the data was collected and analysed (KEK-BE 166/2014).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesChildhood cancer is a rare disease and to avoid identification of individual patients, data is not available online. The data that support the findings of this study are available upon reasonable request. All data requests should be communicated to the corresponding author at the Institute of Social and Preventive Medicine, University of Bern, Switzerland.